Novo Nordisk's shares surged on Friday following the announcement of promising early-stage results for its weekly amycretin obesity drug. The trial revealed an average weight reduction of 22% in obese and overweight patients after 36 weeks.
Novo Nordisk's shares surged on Friday following the announcement of promising early-stage results for its weekly amycretin obesity drug. The trial revealed an average weight reduction of 22% in obese and overweight patients after 36 weeks.